TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily
Brief Summary: The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.


Options:
A: Intervention Type: DRUG; Name: Tiotropium + SERETIDE 50/500; Assigned to Arm(s): N/A
B: Arm Label: Symbicort+TIO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug) | Arm Label: Spiriva® + Placebo Turbuhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva (tiotropium bromide 18ug) | Intervention Type: DRUG; Name: Symbicort (budesonide/formoterol turbuhaler 320/9ug); Assigned to Arm(s): Symbicort+TIO | Intervention Type: DRUG; Name: Spiriva (tiotropium bromide 18ug); Assigned to Arm(s): Spiriva® + Placebo Turbuhaler
C: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily
Brief Summary: The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.


Options:
A: Arm Label: Symbicort+TIO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug) | Arm Label: Spiriva® + Placebo Turbuhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva (tiotropium bromide 18ug) | Intervention Type: DRUG; Name: Symbicort (budesonide/formoterol turbuhaler 320/9ug); Assigned to Arm(s): Symbicort+TIO | Intervention Type: DRUG; Name: Spiriva (tiotropium bromide 18ug); Assigned to Arm(s): Spiriva® + Placebo Turbuhaler
B: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
C: Intervention Type: DRUG; Name: budesonide/formoterol, 2x 200/6 microgram. 4 times daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisolone, 30 mg once daily and placebo; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: terbutaline sulfate (Bricasol) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: budesonide (Pulmicort), Drug: terbutaline sulfate (Bricasol) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort), Drug: terbutaline sulfate (Bricasol) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: budesonide (Pulmicort); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: terbutaline sulfate (Bricasol); Assigned to Arm(s): 1, 2, 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily
Brief Summary: The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.


Options:
A: Arm Label: N/A (Survey study); Type: N/A; Interventions: Other: Non-Interventional | Intervention Type: OTHER; Name: Non-Interventional; Assigned to Arm(s): N/A (Survey study)
B: Intervention Type: DRUG; Name: Tiotropium + SERETIDE 50/500; Assigned to Arm(s): N/A
C: Arm Label: Symbicort+TIO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug) | Arm Label: Spiriva® + Placebo Turbuhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva (tiotropium bromide 18ug) | Intervention Type: DRUG; Name: Symbicort (budesonide/formoterol turbuhaler 320/9ug); Assigned to Arm(s): Symbicort+TIO | Intervention Type: DRUG; Name: Spiriva (tiotropium bromide 18ug); Assigned to Arm(s): Spiriva® + Placebo Turbuhaler
D: Arm Label: ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate/Salmeterol | Arm Label: SPIRIVA® HANDIHALER® inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium Bromide | Intervention Type: DRUG; Name: Tiotropium Bromide; Assigned to Arm(s): SPIRIVA® HANDIHALER® inhaler | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol; Assigned to Arm(s): ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily
Brief Summary: The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.


Options:
A: Arm Label: Symbicort+TIO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug) | Arm Label: Spiriva® + Placebo Turbuhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva (tiotropium bromide 18ug) | Intervention Type: DRUG; Name: Symbicort (budesonide/formoterol turbuhaler 320/9ug); Assigned to Arm(s): Symbicort+TIO | Intervention Type: DRUG; Name: Spiriva (tiotropium bromide 18ug); Assigned to Arm(s): Spiriva® + Placebo Turbuhaler
B: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): N/A
D: Arm Label: Tiotropium Respimat 5mcg (Tio R5); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Tiotropium Respimat 10mcg (Tio R10); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Tiotropium Inhalation Solution; Assigned to Arm(s): Tiotropium Respimat 10mcg (Tio R10), Tiotropium Respimat 5mcg (Tio R5) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily
Brief Summary: The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.


Options:
A: Arm Label: Symbicort+TIO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort (budesonide/formoterol turbuhaler 320/9ug) | Arm Label: Spiriva® + Placebo Turbuhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spiriva (tiotropium bromide 18ug) | Intervention Type: DRUG; Name: Symbicort (budesonide/formoterol turbuhaler 320/9ug); Assigned to Arm(s): Symbicort+TIO | Intervention Type: DRUG; Name: Spiriva (tiotropium bromide 18ug); Assigned to Arm(s): Spiriva® + Placebo Turbuhaler
B: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate and fluticasone propionate | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate and fluticasone propionate; Assigned to Arm(s): Arm 1
D: Intervention Type: DRUG; Name: budesonide/formoterol, 2x 200/6 microgram. 4 times daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisolone, 30 mg once daily and placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stent vs. Angioplasty for Treatment of Thrombosed AV Grfats: Long-Term Outcomes
Brief Summary: Arteriovenous grafts are used as the vascular access in 40-50% of hemodialysis patients. Grafts are prone to recurrent stenosis (narrowing) and thrombosis (clotting). Graft clotting is usually due to a narrowing at the site where the graft joins the vein. The standard treatment is to remove the clot and angioplasty the narrowed area. The long-term outcome is not good, lasting only about 1 month. Placing a stent (a small metallic, PTFE covered, spring) at the narrowed site may keep the graft open longer. Principal investigator's preliminary research data suggest that placing a stent at the stenotic site prolongs graft patency following thrombectomy, as compared to conventional angioplasty.

This is a single-center, randomized clinical trial, in which patients with a clotted graft with underlying stenosis at the venous anastomosis of the graft will be allocated to thrombectomy + angioplasty (control group) or to thrombectomy + stent placement (study group). The primary endpoint will be primary (unassisted) graft patency. The secondary endpoints will be secondary (assisted) graft patency and overall access-related costs.


Options:
A: Intervention Type: PROCEDURE; Name: angioplasty; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: stent placement; Assigned to Arm(s): N/A
B: Arm Label: Balloon thrombectomy; Type: EXPERIMENTAL; Interventions: Device: Balloon thrombectomy | Arm Label: Thromboaspiration system; Type: EXPERIMENTAL; Interventions: Device: Thromboaspiration system | Intervention Type: DEVICE; Name: Balloon thrombectomy; Assigned to Arm(s): Balloon thrombectomy | Intervention Type: DEVICE; Name: Thromboaspiration system; Assigned to Arm(s): Thromboaspiration system
C: Arm Label: VIABAHN Treatment Group; Type: EXPERIMENTAL; Interventions: Device: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface | Arm Label: PTA Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty | Intervention Type: DEVICE; Name: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface; Assigned to Arm(s): VIABAHN Treatment Group | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): PTA Treatment Group
D: Arm Label: Conventional Balloon Angioplasty (COBA); Type: ACTIVE_COMPARATOR; Interventions: Device: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: Drug Eluting Balloon Angioplasty (DEB); Type: EXPERIMENTAL; Interventions: Device: Percutaneous Transluminal Angioplasty (PTA) | Intervention Type: DEVICE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): Drug Eluting Balloon Angioplasty (DEB) | Intervention Type: DEVICE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): Conventional Balloon Angioplasty (COBA)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial
Brief Summary: The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation. The safety of this treatment will also be studied.


Options:
A: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
B: Arm Label: 1. YM150, Dose W, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 2. YM150, Dose X, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 3. YM150, Dose X, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 4. YM150, Dose Y once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 5. YM150, Dose Y twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 6. YM150, Dose Z, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 7. Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: YM150; Assigned to Arm(s): 1. YM150, Dose W, twice daily, 2. YM150, Dose X, once daily, 3. YM150, Dose X, twice daily, 4. YM150, Dose Y once daily, 5. YM150, Dose Y twice daily, 6. YM150, Dose Z, once daily | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): 7. Warfarin
C: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Acetylasalicylic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Acetylasalicylic acid
D: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin K antagonist (warfarin or acenocoumarol) tablets; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Screening for Lung Cancer. A Randomised Controlled Trial of Low-Dose CT-Scanning.
Brief Summary: The trial is a randomised trial comparing annual CT screening for lung cancer with no screening in 4104 smokers and former smokers between the age of 50 and 70 years. The goals are: 1) to evaluate if annual CT screening can reduce lung cancer mortality by more than 20 % (in collaboration with the NELSON trial in the Netherlands, 2) to evaluate psychological effects of screening including the effects of false positive diagnoses, and 3) to evaluate possible effects on smoking behaviour. The trial is funded in full by the Danish Ministry of Interior and Health.


Options:
A: Intervention Type: PROCEDURE; Name: annual CT screening; Assigned to Arm(s): N/A
B: Arm Label: Feedback on lung age and exhaled carbon monoxide; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lung Age feedback and exhaled carbon monoxide | Arm Label: No lung age feedback; Type: SHAM_COMPARATOR; Interventions: Behavioral: No Lung Age Feedback | Intervention Type: BEHAVIORAL; Name: Lung Age feedback and exhaled carbon monoxide; Assigned to Arm(s): Feedback on lung age and exhaled carbon monoxide | Intervention Type: BEHAVIORAL; Name: No Lung Age Feedback; Assigned to Arm(s): No lung age feedback
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Carotid ultrasound for plaque screening, Behavioral: Brief advice for smoking cessation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief advice for smoking cessation | Intervention Type: DEVICE; Name: Carotid ultrasound for plaque screening; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Brief advice for smoking cessation; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: motivational counseling | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Intervention Type: BEHAVIORAL; Name: motivational counseling; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tobacco Use in Opioid Agonist Treated Pregnant Women
Brief Summary: The primary objective of the proposed study is to evaluate the efficacy of tobacco abstinence-contingent voucher incentives versus non-tobacco abstinence-contingent incentives for reducing or eliminating tobacco use during pregnancy in methadone treated women. In addition, the impact that this intervention has in reducing the incidence and severity of methadone associated neonatal abstinence syndrome will also be examined.


Options:
A: Arm Label: tobacco abstinent contingent voucher; Type: EXPERIMENTAL; Interventions: Behavioral: tobacco abstinent contingent | Arm Label: non-contingent; Type: EXPERIMENTAL; Interventions: Behavioral: non-contingent | Arm Label: no voucher; Type: OTHER; Interventions: Behavioral: control | Intervention Type: BEHAVIORAL; Name: tobacco abstinent contingent; Assigned to Arm(s): tobacco abstinent contingent voucher | Intervention Type: BEHAVIORAL; Name: non-contingent; Assigned to Arm(s): non-contingent | Intervention Type: BEHAVIORAL; Name: control; Assigned to Arm(s): no voucher
B: Arm Label: Original contingent vouchers schedule; Type: EXPERIMENTAL; Interventions: Behavioral: Voucher-based incentives | Arm Label: Revised contingent vouchers schedule; Type: EXPERIMENTAL; Interventions: Behavioral: Voucher-based incentives | Arm Label: Non-contingent vouchers schedule; Type: SHAM_COMPARATOR; Interventions: Behavioral: Voucher-based incentives | Intervention Type: BEHAVIORAL; Name: Voucher-based incentives; Assigned to Arm(s): Non-contingent vouchers schedule, Original contingent vouchers schedule, Revised contingent vouchers schedule
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling from WTQL | Arm Label: Incentive; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling from WTQL, Other: Financial incentive to participate | Intervention Type: BEHAVIORAL; Name: Counseling from WTQL; Assigned to Arm(s): Control, Incentive | Intervention Type: OTHER; Name: Financial incentive to participate; Assigned to Arm(s): Incentive
D: Arm Label: Smoking-cessation treatment + substance treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Smoking-cessation treatment | Arm Label: Substance-treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Smoking-cessation treatment; Assigned to Arm(s): Smoking-cessation treatment + substance treatment as usual

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Additional Exercise Therapy in Patients With Peripheral Arterial Disease: The Value of Supervised Exercise Therapy After Invasive Treatment of Peripheral Arterial Disease.
Brief Summary: The objective of this study is to investigate what the value is of SET after a radiological or surgical intervention for peripheral arterial disease in the aorto-iliacal, femoro-popliteal and crural segments in comparison with a control group.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Exercise | Intervention Type: BEHAVIORAL; Name: Walking Exercise; Assigned to Arm(s): 1, 2
C: Arm Label: Angioplasty / surgery and exercise therapy; Type: EXPERIMENTAL; Interventions: Procedure: Angioplasty / surgery and exercise therapy | Arm Label: Angioplasty / surgery; Type: NO_INTERVENTION; Interventions: Procedure: angioplasty / surgery | Intervention Type: PROCEDURE; Name: angioplasty / surgery; Assigned to Arm(s): Angioplasty / surgery | Intervention Type: PROCEDURE; Name: Angioplasty / surgery and exercise therapy; Assigned to Arm(s): Angioplasty / surgery and exercise therapy
D: Arm Label: Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength Training | Arm Label: Walking training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Walking Training | Intervention Type: BEHAVIORAL; Name: Walking Training; Assigned to Arm(s): Walking training | Intervention Type: BEHAVIORAL; Name: Strength Training; Assigned to Arm(s): Strength training

Answer: C